Cargando…

Oligosaccharides as Potential Therapeutics against Atherosclerosis

Atherosclerosis is the major cause of cardiovascular-disease-related death worldwide, resulting from the subendothelial accumulation of lipoprotein-derived cholesterol, ultimately leading to chronic inflammation and the formation of clinically significant atherosclerotic plaques. Oligosaccharides ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabravolski, Siarhei A., Sukhorukov, Vasily N., Melnichenko, Alexandra A., Khotina, Victoria A., Orekhov, Alexander N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386248/
https://www.ncbi.nlm.nih.gov/pubmed/37513323
http://dx.doi.org/10.3390/molecules28145452
_version_ 1785081616796745728
author Dabravolski, Siarhei A.
Sukhorukov, Vasily N.
Melnichenko, Alexandra A.
Khotina, Victoria A.
Orekhov, Alexander N.
author_facet Dabravolski, Siarhei A.
Sukhorukov, Vasily N.
Melnichenko, Alexandra A.
Khotina, Victoria A.
Orekhov, Alexander N.
author_sort Dabravolski, Siarhei A.
collection PubMed
description Atherosclerosis is the major cause of cardiovascular-disease-related death worldwide, resulting from the subendothelial accumulation of lipoprotein-derived cholesterol, ultimately leading to chronic inflammation and the formation of clinically significant atherosclerotic plaques. Oligosaccharides have been widely used in biomedical research and therapy, including tissue engineering, wound healing, and drug delivery. Moreover, oligosaccharides have been consumed by humans for centuries, and are cheap, and available in large amounts. Given the constantly increasing number of obesity, diabetes, and hyperlipidaemia cases, there is an urgent need for novel therapeutics that can economically and effectively slow the progression of atherosclerosis. In this review, we address the current state of knowledge in oligosaccharides research, and provide an update of the recent in vitro and in vivo experiments that precede clinical studies. The application of oligosaccharides could help to eliminate the residual risk after the application of other cholesterol-lowering medicines, and provide new therapeutic opportunities to reduce the associated burden of premature deaths because of atherosclerosis.
format Online
Article
Text
id pubmed-10386248
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103862482023-07-30 Oligosaccharides as Potential Therapeutics against Atherosclerosis Dabravolski, Siarhei A. Sukhorukov, Vasily N. Melnichenko, Alexandra A. Khotina, Victoria A. Orekhov, Alexander N. Molecules Review Atherosclerosis is the major cause of cardiovascular-disease-related death worldwide, resulting from the subendothelial accumulation of lipoprotein-derived cholesterol, ultimately leading to chronic inflammation and the formation of clinically significant atherosclerotic plaques. Oligosaccharides have been widely used in biomedical research and therapy, including tissue engineering, wound healing, and drug delivery. Moreover, oligosaccharides have been consumed by humans for centuries, and are cheap, and available in large amounts. Given the constantly increasing number of obesity, diabetes, and hyperlipidaemia cases, there is an urgent need for novel therapeutics that can economically and effectively slow the progression of atherosclerosis. In this review, we address the current state of knowledge in oligosaccharides research, and provide an update of the recent in vitro and in vivo experiments that precede clinical studies. The application of oligosaccharides could help to eliminate the residual risk after the application of other cholesterol-lowering medicines, and provide new therapeutic opportunities to reduce the associated burden of premature deaths because of atherosclerosis. MDPI 2023-07-17 /pmc/articles/PMC10386248/ /pubmed/37513323 http://dx.doi.org/10.3390/molecules28145452 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dabravolski, Siarhei A.
Sukhorukov, Vasily N.
Melnichenko, Alexandra A.
Khotina, Victoria A.
Orekhov, Alexander N.
Oligosaccharides as Potential Therapeutics against Atherosclerosis
title Oligosaccharides as Potential Therapeutics against Atherosclerosis
title_full Oligosaccharides as Potential Therapeutics against Atherosclerosis
title_fullStr Oligosaccharides as Potential Therapeutics against Atherosclerosis
title_full_unstemmed Oligosaccharides as Potential Therapeutics against Atherosclerosis
title_short Oligosaccharides as Potential Therapeutics against Atherosclerosis
title_sort oligosaccharides as potential therapeutics against atherosclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386248/
https://www.ncbi.nlm.nih.gov/pubmed/37513323
http://dx.doi.org/10.3390/molecules28145452
work_keys_str_mv AT dabravolskisiarheia oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis
AT sukhorukovvasilyn oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis
AT melnichenkoalexandraa oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis
AT khotinavictoriaa oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis
AT orekhovalexandern oligosaccharidesaspotentialtherapeuticsagainstatherosclerosis